Results 31 to 40 of about 3,067,072 (318)
Clinical use of Jak 1 inhibitors for rheumatoid arthritis
, 2021 The uptake of Jak inhibitors in the RA space has been among the most rapid in rheumatology, based on the results of comprehensive clinical trial programmes of five agents.
Nash, Peter
core +1 more source
Network pharmacology of JAK inhibitors [PDF]
Proceedings of the National Academy of Sciences, 2016 SignificanceJAK kinase inhibitors (JAKis) have advanced options for treatment of autoimmune diseases. Because JAKs are signaling hubs for several cytokine receptors, JAKis’ overall impact on the immune system and how they actually improve diseases like rheumatoid arthritis remain poorly understood.
Devapregasan, Moodley +10 more
openaire +2 more sources
JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications
Annals of the Rheumatic Diseases, 2023 Objectives To estimate the association of Janus kinase inhibitors (JAKi) with the incidence of malignancy, compared with placebo, tumour necrosis factor (TNF)-α inhibitors (TNFi) and methotrexate.
M. Russell +12 more
semanticscholar +1 more source
ACR Open Rheumatology, 2022 Objective Janus kinase (JAK) inhibition effectively treats immune‐mediated inflammatory diseases (IMIDs); however, concern over the risk of major adverse cardiac events (MACE) and venous thromboembolism (VTE) remains. We aimed to evaluate the safety (VTE
Muhammad Haisum Maqsood +5 more
doaj +1 more source
Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy. [PDF]
, 2022 OBJECTIVES JAK Inhibitors (JAKi) are recommended DMARDs for patients with moderate-to severe rheumatoid arthritis (RA) who failed first-line therapy with methotrexate.
Mueller, Ruediger +10 more
core +1 more source
Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature
Medicina, 2023 Background: Hidradenitis suppurativa (HS), also known as acne inversa or Verneuil’s disease, is a chronic, inflammatory, recurrent, and debilitating skin disease of the hair follicles characterized by inflammatory, painful, deep-rooted lesions in the ...
F. Martora +5 more
semanticscholar +1 more source
JAK inhibitors for inflammatory bowel disease: recent advances
Frontline Gastroenterology, 2023 Inflammatory bowel disease (IBD) commonly requires immunosuppressive treatments to induce and maintain durable remission. Janus kinase inhibitors (JAKis) are a novel group of orally administered, small molecule drugs that work by attenuating multiple ...
S. Honap +7 more
semanticscholar +1 more source
JAK inhibitors: new indication and emerging safety data in 2022
, 2022 Janus kinase inhibitors continue to show promise in a diverse range of indications, but administration of these drugs needs careful consideration of the benefits and risks.
Nash, P
core +1 more source
Scientific Reports, 2022 Increasing number of Janus kinase (JAK) inhibitors have been approved for chronic haematopoietic neoplasms and inflammatory/autoimmune diseases.
L. Hoisnard +13 more
semanticscholar +1 more source
Skin Health and Disease, 2023 Background Janus kinase (JAK) inhibitors are being evaluated as promising upcoming treatments for atopic dermatitis (AD). Objectives To systematically assess the efficacy of oral JAK inhibitors in patients with AD and provide comparisons among JAK ...
Kevin P. Lee +3 more
doaj +1 more source